Back to News
Market Impact: 0.4
Pfizer's TUKYSA Gets FDA Nod For Front-Line HER2+ Breast Cancer Maintenance
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
The FDA approved Pfizer's TUKYSA in combination with trastuzumab and pertuzumab for maintenance treatment of adults with HER2-positive, unresectable locally advanced or metastatic disease. The approval expands the drug's approved use; the article provides no sales estimates or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
PFE0.80
More News
- Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
- Roche Gets FDA Approval for Another Label Expansion of Tecentriq
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
- SpaceX’s Wireless Threat Rises With Spectrum Deal
- Why is the Chinese stock market missing the AI rally
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback